✦ LIBER ✦

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17

✍ Scribed by Karapetis, C. S.; Jonker, D.; Daneshmand, M.; Hanson, J. E.; O'Callaghan, C. J.; Marginean, C.; Zalcberg, J. R.; Simes, J.; Moore, M. J.; Tebbutt, N. C.; Price, T. J.; Shapiro, J. D.; Pavlakis, N.; Gibbs, P.; Van Hazel, G. A.; Lee, U.; Haq, R.; Virk, S.; Tu, D.; Lorimer, I. A. J.

Book ID: 125459423
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 706 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.ccr-13-0606

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of PTEN, BRAF and PI3K status f

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

✍ Tural, Deniz; Batur, Sebnem; Erdamar, Sibel; Akar, Emre; Kepil, Nuray; Mandel, N 📂 Article 📅 2013 🏛 S. Karger AG 🌐 English ⚖ 467 KB

Impact of KRAS and BRAF Gene Mutation St

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

✍ Price, T. J.; Hardingham, J. E.; Lee, C. K.; Weickhardt, A.; Townsend, A. R.; Wr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 273 KB

KRAS and BRAF Mutations in Advanced Colo

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

✍ Richman, S. D.; Seymour, M. T.; Chambers, P.; Elliott, F.; Daly, C. L.; Meade, A 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 164 KB